Pregnancy Outcomes After Exposure to Certolizumab Pegol
نویسندگان
چکیده
منابع مشابه
Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
OBJECTIVE To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). METHODS The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. ...
متن کاملPregnancy outcomes after maternal exposure to rituximab.
Rituximab is a chimeric anti-CD20 monoclonal B cell-depleting antibody indicated for certain hematologic malignancies and active rheumatoid arthritis with inadequate response to tumor necrosis factor antagonists. Despite counseling to avoid pregnancy, women may inadvertently become pregnant during or after rituximab treatment. Using the rituximab global drug safety database, we identified 231 p...
متن کاملImpact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
OBJECTIVE Patient-reported outcomes (PROs) provide an opportunity to collect important information relating to patient well-being, which is often difficult for physicians to measure (e.g., quality of life, pain, fatigue, and sleep). Here we evaluate the effects of certolizumab pegol (CZP) on PROs during the 24-week, double-blind phase of the RAPID axial spondyloarthritis (SpA) trial, a phase 3 ...
متن کاملActive axial spondyloarthritis: potential role of certolizumab pegol
The axial spondyloarthropathies are a group of chronic inflammatory diseases that predominantly affect the axial joints. This group includes ankylosing spondylitis and nonradiographic axial spondyloarthropathy. While the pathogenesis of axial spondyloarthropathies is not clear, immunologically active tissues primarily include the entheses, ie, the areas where ligaments, tendons, and joint capsu...
متن کاملExposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
BACKGROUND Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS Adults (N = 2157) with Crohn's disease were treated with CZP in nine c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis & Rheumatology
سال: 2018
ISSN: 2326-5191
DOI: 10.1002/art.40508